A new article published in Therapeutic Advances in Gastroenterology reported that highly selective serotonergic receptor agonists have been developed for instance prucalopride which are effective in stimulating gut motility and are devoid of cardiac side effects. Prucalopride has now been approved for the management of chronic idiopathic constipation in several countries. It was stated that multiple multicenter randomized placebo controlled clinical trials have demonstrated superiority of prucalopride over placebo on short to medium term treatment in relieving major symptoms of constipation in both men and women across a broad spectrum of ages ethnicities and geographic locations. The article also discussed favorable safety profile of prucalopride and also highlighted the lack of data indicating arrythmogenicity associated with this drug. This article further disclosed that the evidence for efficacy of the drug in other forms of constipation such as opioid induced constipation and that related to Parkinson s disease is in the process of emerging.1 Reference 1. Omer A Quigley EMM. An update on prucalopride in the treatment of chronic constipation. Therapeutic Advances in Gastroenterology. 2017 10 11 877 887. doi 10.1177 1756283X17734809.